This week's highlights: The FDA grants breakthrough designation to next-generation CAR-T therapy, novel PSMA radioligand shows promise in reducing salivary toxicity, major AI regulation initiatives advance, and clinical trials push radioligand theranostics into earlier treatment lines. This digest compiles official announcements, peer-reviewed research, and expert commentary from January 24-30, 2026.
Artificial Intelligence
California AI Transparency Act Takes Effect
State Regulation Active NowCalifornia's Transparency in Frontier AI Act (SB 53) became effective, requiring developers of large AI models trained using greater than 10²⁶ FLOPS to publish risk frameworks, report critical safety incidents within 15 days, and implement whistleblower protections, with penalties up to $1 million per violation.
Impact: Sets precedent for state-level AI oversight as federal regulation remains uncertain. Developers must establish new compliance infrastructure.
DeepSeek R1 Reshapes Open-Source AI Landscape
Open Source Chinese InnovationChinese firm DeepSeek released R1, an open-source reasoning model that demonstrated what relatively small firms can achieve with limited resources. The release triggered a "DeepSeek moment" among AI developers, with the term becoming shorthand for unexpected Chinese AI capabilities.
Expert perspective: Despite US-China tensions, open-source Chinese models are gaining goodwill in the global AI community, with the gap between Chinese releases and Western advancements narrowing from months to weeks.
AI Agents Enter Enterprise Deployment
ImplementationCompanies accelerate AI agent deployment as first visible manifestation of increased AI investments. CEOs focus on preparing customers and employees for AI-augmented workflows.
Trend: 2026 is emerging as the year AI moves from hype to pragmatic implementation, with emphasis on fine-tuned small language models (SLMs) offering superior cost-performance for enterprise applications.
Nucs AI Establishes Medical Advisory Board for Theranostics
AI + Theranostics Advisory BoardNucs AI announced formation of Medical Advisory Board to accelerate adoption of AI-driven theranostics. As radioligand therapies expand in oncology, AI-based treatment response measurement and disease behavior tracking become increasingly critical.
Significance: Highlights growing premium on clinical oversight, evidence generation, and alignment with real-world care pathways as AI enters clinical decision-making for radioligand therapy.
AI in Healthcare Research - Recent Publications
- Bibliometric Analysis (January 2026): 67.7% annual growth in AI health professions education research, with 185 publications totaling 5,257 citations. Exceptional 84.3% international collaboration rate positions AI educational research as mature discipline.
- Diagnostic AI Tool Development (South India): Study protocol published for ML prediction tool for differential diagnosis of tropical fevers, employing Support Vector Machine, logistic regression, and ensemble models.
- Developmental Coordination Disorder (January 22, 2026): Scoping review published in Children mapping AI use in evaluation and intervention of DCD. Seven studies (2021-2025) identified, highlighting emerging methodologies.
Gene Therapy & Cell Therapy
FDA Grants Breakthrough Designation to Allogeneic CAR-T
FDA Breakthrough Allogeneic CAR-TFDA conferred breakthrough therapy designation to soficabtagene geleucel (sofi-cel; WU-CART-007) by Wugen, Inc. for treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic lymphoma (LBL).
Innovation: Off-the-shelf allogeneic CAR-T targeting CD7 using CRISPR/Cas9 gene editing to delete CD7 and TRAC genes, preventing CAR T-cell fratricide and mitigating graft-vs-host disease risk.
Phase 1/2 Data (Blood, NCT04984356): 90.9% ORR in 11 evaluable patients receiving enhanced lymphodepleting chemotherapy plus RP2D, including 72.7% complete remission rate.
View Pivotal T-RRex Trial (NCT06514794)FDA Announces Flexible CMC Approach for Cell & Gene Therapies
Regulatory Flexibility CMC RequirementsFDA announced increased flexibility for chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies. The change applies to clinical development, commercial specifications, and process validation.
Significance: Formalizes regulatory flexibilities that CBER has been applying case-by-case, aiming to make approaches more transparent and accessible to all CGT developers.
CBER 2026 Guidance Agenda includes: Draft guidances on FDA's plausible mechanism pathway for individualized therapies for rare genetic disorders, leveraging prior knowledge in gene therapy development, and CAR-T cell products for non-oncology indications.
ACGT Launches CGTxchange Platform for Shelved Therapies
Rescue Initiative AI-Enabled PlatformASGCT partnered with Orphan Therapeutics Accelerator (OTXL) to create CGTxchange, addressing critical challenge: hundreds of promising cell and gene therapies being shelved not due to lack of efficacy, but because they don't meet traditional commercial viability standards.
Function: Clearinghouse and marketplace for deprioritized therapies, using AI-enabled platform to catalog shelved treatments and connect them with organizations ready to advance development.
Base-Edited Gene Therapy Shows 82% Remission in T-ALL
Phase 1/2 Data Base EditingGreat Ormond Street Hospital researchers published results in New England Journal of Medicine for base-edited gene therapy treating T-cell acute lymphoblastic leukemia.
Results (11 patients, 9 children, starting 2022): 82% achieved deep remission, 64% now disease-free, with only manageable and tolerable side effects.
FDA Lifts Clinical Hold on Intellia's MAGNITUDE-2 Trial
Clinical Hold Lifted ATTR-PNFDA lifted clinical hold on Intellia Therapeutics' Phase 3 MAGNITUDE-2 trial (NCT06672237) evaluating gene editing therapy nexiguran ziclumeran (nex-z, NTLA-2001) for transthyretin amyloidosis with polyneuropathy (ATTR-PN).
FDA Places Holds on REGENXBIO MPS Trials
Clinical HoldFDA placed clinical holds on REGENXBIO's trials for RGX-111 (MPS I/Hurler syndrome) and clemidsogene lanparvovec (RGX-121) (MPS II/Hunter syndrome). Both are AAV vector-based gene therapies.
Genprex Advances Diabetes Gene Therapy Program
Type 1 & 2 Diabetes Beta Cell RejuvenationGenprex commenced preclinical studies in Type 2 diabetes animal models, expanding beyond Type 1 diabetes. GPX-002 demonstrated in vivo proof-of-concept, rejuvenating exhausted beta cells and normalizing glucose levels in T2D models.
Regulatory: FDA pre-IND meeting scheduled Q1 2026 to discuss IND-enabling preclinical studies.
Key Publications & Research Updates
- Link Industries launches with $60M Series A (December 15, 2025): Creating next-gen CAR-T therapies, led by Johnson & Johnson's VC arm.
- Rockefeller University TCR Research: New findings on T-cell receptor signaling using lipid mixture replicating in vivo environment, showing TCRs activate when encountering antigens—counter to previous cryo-EM analyses.
- Clinical Cancer Research: Pancreatic cancer organoids with TILs predict combination therapy success (ACGT SAC Chair Michael T. Lotze, MD).
- Cell: pTα enhances mRNA translation and potentiates CAR T cells for solid tumor eradication (Michel Sadelain, MD, PhD).
- Nature Biomedical Engineering: mRNA engineering of allogeneic MSCs enables coordinated T cell engager delivery (Christopher Jewell, PhD).
Radioligand Theranostics
Radiopharm Theranostics: RAD 101 Shows 92% MRI Concordance
Brain Metastases FDA Fast TrackRAD 101 Phase 2b interim results: 92% of evaluable patients (12 of first patients) achieved MRI concordance—the primary endpoint—in imaging study of brain metastases from solid tumors.
Implications: Results align with Phase 2a data. If confirmed, will trigger preparation of multi-center, multi-country Phase 3 registrational trial. Study anticipates completing enrollment Q1 2026.
Market: Over 300,000 patients diagnosed annually in U.S. with cerebral metastases. RAD 101 has FDA Fast Track Designation.
RAD 202 & RAD 204: DSMC Approves Dose Escalation
HER2+ & PD-L1 Dose EscalationRAD 202 (HER2-targeted): Phase 1 'HEAT' trial in HER2+ advanced solid tumors. DSMC recommended progression to next dose level (75mCi). Demonstrated clinical proof-of-concept with positive safety and biodistribution.
RAD 204 (PD-L1-targeted): Completed enrollment of second cohort in PD-L1-driven cancers (NSCLC, SCLC, TNBC, melanoma, HNSCC, endometrial cancer). DSMC approved third cohort dosing at 90mCi Lu-177. Two of three patients (30mCi cohort) showed stable disease for 5.5 months in metastatic NSCLC vs. 3.5 months historical SOC PFS.
Safety: Reassuring profile with no drug-related adverse events reported across both programs.
RAD 402 (Tb-161) & RV 01: Phase 1 Trials Launching Q1 2026
Prostate Cancer Terbium-161 & B7H3Tb-161-RAD 402 (KLK3-targeting mAb with Terbium-161): Received Bellberry HREC approval for FIH Phase 1 trial in metastatic/locally advanced prostate cancer. Trial initiation expected Q1 2026. Preclinical data showed strong tumor targeting, limited bone/marrow uptake, hepatic excretion.
Lu-177-RV 01 (B7H3 4Ig isoform-targeting mAb): FDA clearance received to advance into Phase 1 clinical trial. Radiopharm increased ownership in Radiopharm Ventures from 75% to 87.5% as joint venture shows promise.
Novel PSMA Radioligand Reduces Salivary Gland Toxicity
Toxicity Reduction PSMA-1-DOTACase Comprehensive Cancer Center researchers published preclinical findings in Molecular Imaging and Biology for PSMA-1-DOTA, a novel PSMA-targeting ligand with favorable binding characteristics and reduced salivary gland uptake compared to existing treatments.
Significance: Severe salivary gland toxicity (xerostomia) from alpha emissions has led patients to reject or prematurely discontinue PSMA-targeted radioligand therapy. Previous mitigation approaches showed limited success.
Expert commentary: "This breakthrough could fundamentally change prostate cancer care by transforming PSMA-targeted therapy from a 'last resort' option to an earlier intervention" — Dr. Zhenghong Lee, Co-leader Cancer Imaging Program.
UCLA Launches ANDROMEDA Trial: Lu-177 vs Ac-225 Direct Comparison
Phase 2 Trial Alpha vs Beta EmitterUCLA Health Jonsson Comprehensive Cancer Center opened ANDROMEDA trial—first study to directly compare lutetium-177–PSMA-617 versus actinium-225–PSMA-617 when combined with SBRT in oligorecurrent prostate cancer.
Rationale: "While we previously showed adding Lu-177 to SBRT can prolong survival without progression, we think Ac-225 may be even more effective at targeting microscopic disease" — Dr. Amar Kishan, Executive Vice Chair Radiation Oncology.
Context: Builds on LUNAR trial showing encouraging results combining Lu-177-based therapy and SBRT.
Enrollment Contact: [email protected]ARTISAN Trial: Alpha Radioligand Expands to International Sites
Alpha-emitter International ExpansionPhase 1 ARTISAN trial plans to expand enrollment to patients with metastatic CRPC outside the U.S. in second half of 2026. Trial evaluating novel alpha radioligand in two cohorts.
Eligibility: Age ≥18 years, ECOG 0-2, progressive mCRPC, prior AR pathway inhibitor, ≥1 PSMA-avid distant metastatic lesion, adequate organ function.
PSMA Radioligand + SBRT Doubles Progression-Free Survival
Published Data PFS DoubledFirst randomized trial showing PSMA-targeting radioligand significantly delays progression when added to metastasis-directed radiation. Men receiving radioligand drug: median 17.6 months without progression vs 7.4 months for SBRT alone.
Impact: Translates to significant delay in hormone therapy initiation, which carries side effects (fatigue, bone loss). UCLA Health Jonsson Comprehensive Cancer Center.
Tb-161 PSMA: Next-Generation Radioligand Update
- Frontiers in Oncology Review (January 13, 2026): Comprehensive synthesis of Tb-161-PSMA mechanism, radiolabeling, dosimetry, preclinical results, and clinical outcomes. Dual-emission mechanism (beta + Auger/conversion electrons) enables treatment of varying lesion sizes.
- Preclinical superiority: Tb-161-PSMA-617 demonstrated dose-dependent survival increases—36 days (5.0 MBq/mouse) and 65 days (10 MBq/mouse) vs 19 days untreated controls.
- Clinical data (Saarland University, 2024): Six mCRPC patients previously progressing on Lu-177-PSMA or combination therapy. Four of seven patients (57%) showed objective imaging response and ≥50% PSA decline. Well tolerated with only grade 1-2 adverse events.
- Dosimetry advantage: Monte Carlo simulations and preclinical studies confirm Tb-161-PSMA delivers significantly higher radiation dose to tumors with superior therapeutic index vs Lu-177-PSMA.
AACRJOURNALS Cancer Research Abstracts (January 19, 2026)
- Abstract B041: Pb-212-PSMA RLT mechanisms of action. Pb-212-ADVC001 (NCT05720130 Phase I/II) displayed potent cytotoxicity with EC50 of 2.7-7.2 kBq/mL in PSMA+ PC cell lines.
- Abstract PR027: SHAPE cohort characterizing PSMA heterogeneity and RLT resistance determinants. RLT-treated tumors exhibit copy-number-dominant profile vs untreated.
- Abstract B057: Molecular evolution following Lu-177-PSMA-617 in 305 mCRPC patients. AR amplification (24%), PTEN loss (6%), HRR alterations (18%). Patients with AR/PTEN alterations: shorter PFS (HR 1.85) and OS (HR 2.06).
- Abstract B073: CTC protein quantification reveals PSMA expression heterogeneity associated with LuPSMA response. 77 CTC samples from 35 mCRPC patients show PI3K-PSMA signaling crosstalk influences resistance.
📊 This Week in Perspective
Convergence of Technologies: This week highlights accelerating convergence of AI, gene therapy, and radioligand theranostics. Nucs AI's medical advisory board formation exemplifies AI integration into theranostic treatment planning. CGTxchange's AI-enabled platform demonstrates machine learning rescuing shelved therapies. The trend: precision medicine becoming computationally-enhanced precision medicine.
Regulatory Momentum: FDA's flexible CMC approach for CGT and California's AI Transparency Act signal maturation of regulatory frameworks. Breakthrough designations (sofi-cel) and Fast Track status (RAD 101) indicate agencies recognizing urgent unmet needs while maintaining safety standards.
Paradigm Shifts in PSMA Therapy: UCLA's ANDROMEDA trial (Lu-177 vs Ac-225) and novel PSMA-1-DOTA with reduced salivary toxicity represent strategic evolution: moving PSMA radioligand therapy earlier in treatment algorithm, optimizing isotope selection, and eliminating dose-limiting toxicities that relegate therapy to last-resort status.
Looking Ahead — Q1 2026 Catalysts:
- RAD 101: Phase 2b enrollment completion expected Q1 2026
- RAD 402 & RV 01: Phase 1 trial initiations
- ILLUMINATE Project: Clinical trial launch (150 patients) validating metabolic-MRI integrated theranostics approach
- Genprex GPX-002: FDA pre-IND meeting for diabetes gene therapy
- Regulatory: CBER 2026 guidance releases (plausible mechanism pathway, CAR-T non-oncology indications)
In Case You Missed It
IHI ILLUMINATE Project: Addressing Lu-177 Supply & Response Prediction
Manufacturing Metabolic-MRIILLUMINATE project focuses on Lu-177-PSMA for mCRPC. ~30% of patients don't benefit, but clinicians typically realize this after full therapy course. Project developing metabolic-MRI to rapidly assess treatment response and tumor characteristics.
Manufacturing innovation: Improving Lu-177 production steps and developing Ytterbium-176 recycling process to minimize supply shortages. Clinical trial (150 patients) launching 2026.
EVOLUTION Trial: Lu-177 PSMA + Dual Checkpoint Blockade
Combination Therapy ImmunotherapyPhase 2 trial suggests adding dual immune checkpoint blockade to radioligand therapy modestly improves disease control in mCRPC. Median rPFS: 12.0 vs 8.5 months (RLT alone). 12-month rPFS: 47% vs 23%.
Response signals: ORR 71% vs 50%, PSA ≥50% decline 75% vs 67%. 16% in combination arm discontinued radioligand due to deep response. Raises possibility that immune modulation enhances response depth.
RAD 301: Pancreatic Cancer αvβ6-Integrin Imaging Moving to Phase 2
Pancreatic Cancer FDA ODDRAD 301 Phase 1 imaging trial in metastatic pancreatic cancer: 8 of 9 patients dosed (last patient Q1 2026). First six patients demonstrated confirmed safety and significant uptake in AvB6+ lesions.
Strategic pivot: Moving to Phase 2 in loco-regional pancreatic cancer due to larger disease prevalence and unmet need in earlier-stage disease. FDA Orphan Drug Designation previously granted.
In Vivo CAR-T Approaches Enter Early Clinical Testing (2025)
In Vivo CAR-T Manufacturing InnovationIn vivo CAR-T approaches entered FIH studies in 2025, marking translational milestone. Gene delivery systems (viral/non-viral vectors) induce CAR expression directly in patient's immune cells, eliminating ex vivo manufacturing need.
Significance: Early signs of efficacy compelling, though primary endpoints focus on safety, feasibility, immune cell targeting. Critical for patients who have no time to wait for traditional manufacturing timelines.
🔬 Clinical Implementation Insights
For Medical Directors in Radioligand Therapy Trials:
- Patient Selection Optimization: Consider implementing AI-driven PSMA heterogeneity profiling (per SHAPE cohort findings) to predict Lu-177-PSMA response. CTC protein quantification may identify patients with PI3K-driven resistance mechanisms requiring alternative approaches.
- Toxicity Management: Monitor PSMA-1-DOTA clinical translation—potential paradigm shift allowing earlier intervention if salivary toxicity eliminated. May justify earlier-line PSMA RLT protocols.
- Isotope Strategy: Track ANDROMEDA trial results for Lu-177 vs Ac-225 direct comparison data. Tb-161 clinical data suggests therapeutic index advantages for small lesions/micrometastases—relevant for oligorecurrent protocols.
- Biomarker Monitoring: Prompt PSA changes (within 2 days post-first cycle) showing promise as prognostic marker (PubMed 41575546). Consider rapid PSA testing protocols for early response prediction.
For Cell & Gene Therapy Program Leads:
- Regulatory Strategy: FDA's flexible CMC approach and plausible mechanism pathway guidance (coming 2026) may accelerate rare disease programs. Engage CBER early for case-by-case flexibility discussions.
- Manufacturing Innovation: In vivo CAR-T FIH data suggests feasibility—evaluate whether your target allows for in vivo approach to circumvent manufacturing bottlenecks for rapidly progressive diseases.
- Commercial Viability: If deprioritizing promising assets due to commercial constraints, engage ASGCT's CGTxchange platform. AI-enabled matching may identify partners for orphan/rare disease development.